[EN] KRAS G12C INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12C
申请人:MIRATI THERAPEUTICS INC
公开号:WO2020146613A1
公开(公告)日:2020-07-16
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
[EN] COVALENT RAS INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE RAS COVALENTS ET LEURS UTILISATIONS
申请人:REVOLUTION MEDICINES INC
公开号:WO2021108683A1
公开(公告)日:2021-06-03
The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.
A Visible Light and Iron‐mediated Carbocationic Route to Polysubstituted 1‐Halonaphthalenes by Benzannulation using Allylbenzenes and Polyhalomethanes
作者:Irwan Iskandar Roslan、Hongwei Zhang、Kian‐Hong Ng、Stephan Jaenicke、Gaik‐Khuan Chuah
DOI:10.1002/adsc.202001249
日期:2021.2.16
A wide array of polysubstituted 1‐bromo and chloronaphthalenes are obtained from coupling of allylbenzenes and polyhalomethanes. The reaction is mediated by iron metal under visible light irradiation and proceeds via a Kharasch addition intermediate followed by intramolecular FeIII mediated Friedel‐Crafts alkylation, with the formation of two Csp2−Csp2 bonds in the process. This method gives easy access
[EN] QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF<br/>[FR] COMPOSÉS DE QUINAZOLINE, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS
申请人:INVENTISBIO CO LTD
公开号:WO2022002102A1
公开(公告)日:2022-01-06
Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.
A novel class of compounds as KRas G12C inhibitors. Also disclosed are pharmaceutical compositions of the KRas G12C inhibitors and methods of treating KRas G12C associated diseases.